EHA-SWG Scientific Meeting

 

EHA-SWG Scientific Meeting: Hemostasis imbalance: Critical issues and Therapeutic approaches

Dates: September 18-20, 2015
Location: Barcelona, Spain
Chairs: C Balduini, A Falanga

INTRODUCTION

The EHA Scientific Working Group (SWG) Bleeding and thrombosis, SWG Thrombocytopenia and platelet function disorders and EHA organized a workshop on critical issues and therapeutic approaches in disorders of platelets and coagulation leading to either bleeding or thrombosis.

The objectives of this meeting were:

  • Summarizing clinical features and laboratory evaluation of congenital and acquired platelet and clotting factors abnormalities
  • Assessing common acquired disorders of hemostasis leading to bleeding or thrombosis and recognize features of hereditary platelet disorders.
  • Discussion on updates in cancer-associated thrombosis: risk assessment, prevention, and anticoagulant therapy
  • Evaluation of antibody-mediated prothrombotic disorders.
  • Presenting and discussing the advance in venous thromboembolism treatment and features of newer anticoagulant drugs
  • Identifying gaps in thrombotic and bleeding disorders to be incorporated into future research programs.
The meeting included plenary lectures and interactive sessions. A Round table was dedicated to discussion with patient organizations and regulatory issues to better understand the currently unmet needs in these conditions. The faculty supplemented the didactic presentations with panel discussions and case presentations. 
The target group for this meeting were: Specialists in hematology, clinicians, basic researchers, biologists, students and physicians interested in the field of thrombosis and hemostasis or directly involved in clinical management of bleeding and thrombotic diseases. Young hematologists and researchers could also receive a valuable educational benefit from this initiative.
Participants of this meeting were eligible to receive one Continuing Medical Education (CME) credit point for every hour of accredited activity from the EBAH system.
A report of this meeting will be published.

The meeting included plenary lectures and interactive sessions. A Round table was dedicated to discussion with patient organizations and regulatory issues to better understand the currently unmet needs in these conditions. The faculty supplemented the didactic presentations with panel discussions and case presentations. 

The target group for this meeting were: Specialists in hematology, clinicians, basic researchers, biologists, students and physicians interested in the field of thrombosis and hemostasis or directly involved in clinical management of bleeding and thrombotic diseases. Young hematologists and researchers could also receive a valuable educational benefit from this initiative.

Participants of this meeting were eligible to receive one Continuing Medical Education (CME) credit point for every hour of accredited activity from the EBAH system.

A report of this meeting has been published and is now available here.

SPONSORS

          





PROGRAM

Day 1, Friday September 18, 2015

Time Title Speaker
13:00-14:00Registration
14:00-14:15Welcome & Introductory RemarksC Balduini & A Falanga
14:15-14:45Plenary Lecture: New insights into modulation of thrombin formation H Ten Cate
14:45-16:15Management of acquired coagulopathies with massive hemorrhages: The role of plasma, platelet, and coagulation factor concentratesChair: S Eichinger
14:45-15:15Management of the coagulopathy of Acute leukemiasA Falanga
15:15-15:45Management of anticoagulation overdosingS Eichinger
15:45-16:15Management of the acquired coagulation defects I Elalamy
16:15-16:45Coffee break
16:45-18:15Clinical utility of global coagulation assaysChair: M Marchetti
16:45-17:15Goal directed therapy for venous and arterial thrombosis P Simioni
17:15-17:45Global hemostasis Assays in the Management of the Coagulopathy of Trauma B de Laat
17:45-18:15The predictive role of thrombin generation assay in cancer-associated VTE M Marchetti
18:15-20:00Welcome Reception

Day 2, Saturday September 19, 2015

Time Title Speaker
09:00-10:30Latest developments in the thrombotic risk assessmentChair: A Falanga
09:00-09:30Thrombosis: A major contributor to global disease burden in cancer patientsN Kuderer
09:30-10:00The risk assessment of VTE in patients with cancer I Pabinger
11:00-12:30Interactive Session 1: Facing a Thrombophilic stateChair: A Falanga
11:00-11:30Portal vein Thrombosis, Budd Chiari Syndrome and MPNF Leebeek
11:30-12:00Anticoagulant Use during Pregnancy (15 min presentation + 15 min interactive case or self-assessment)R Bauersachs
12:00-12:30Prevention of VTE in patients with multiple myeloma (15 min presentation + 15 min interactive case or self-assessment)F Leebeek
12:30-14:00Lunch
14:00-15:30Current and future treatments for platelet disorders - 1Chair: F Rodeghiero
14:00-14:30Immune thrombocytopenia F Rodeghiero
14:30-15:00Neonatal alloimmune thrombocytopenia J Kjeldsen Kragh
15:00-15:30Heparin induced thrombocytopenia A Greinacher
15:30-16:00Coffee break
16:00-17:00Current and future treatments for platelet disorders - 2 Chair: MA Scully
16:00-16:30Current and future treatments for TTP and HUS MA Scully
16:30-17:00 Current and future treatments for Inherited thrombocytopenias A Pecci
17:00-18:30Evolving use and limitations of new oral anticoagulants for VTE Round table with representatives of patient organizations and pharmaceutical companyChair: H Ten Cate
17:00-17:10IntroductionH ten Cate
17:10-17:25International Self-Monitoring Association of oral Anticoagulated Patients (ISMAAP) C Schaefer
17:25-17:40Dutch Heart FoundationH van Laarhoven
17:40-17:55Development of one of the new oral anticoagulantsJ Van Ryn
17:55-18:30Discussion with the speakers and the audienceAll

Day 3, Sunday September 20, 2015

Time Title Speaker
09:00-09:30Plenary Lecture: Platelets in haemostasis and thrombosis C Gachet
09:30-11:00Bleeding risk and emergencies in subjects with platelet function disordersChair: A Greinacher
09:30-10:00Clinical management of patients with disorders of platelet functionM Cattaneo
10:00-10:30Laboratory characterization of disorders of platelet function P Gresele
10:30-11:00Peri-interventional management of patients receiving anti-platelet therapy A Greinacher
11:00-11:30Coffee break
11:30-13:00Interactive Session 2: Bleeding risk and emergencies in thrombocytopenic subjectsChair: C Balduini
11:30-12:00Which is the “safe” level of platelet count? P Noris
12:00-12:30Are platelet transfusions effective in preventing bleeding in thrombocytopenic patients? M Lozano
12:30-13:00Emergency treatment of hemorrhages in ITPM Michel
13:00-13:10Concluding remarksA Falanga, C Balduini
13:10-14:00Lunch and Departures